SLC5A2 and chronic kidney disease: The effect of SGLT2 inhibitors (vs placebo) on outcomes in the CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials tended to be seen within several months of starting treatment.6, 7, 8 Years-long delays in SGLT2 inhibitor prescription for patients who would benefit from initiating these drugs should therefore be strongly discouraged.